Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 49.0%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 47,200 shares, a drop of 49.0% from the January 31st total of 92,500 shares. Based on an average daily trading volume, of 625,500 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Price Performance

OTCMKTS:ALPMY opened at $9.71 on Friday. Astellas Pharma has a 1-year low of $9.05 and a 1-year high of $13.14. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The firm has a fifty day simple moving average of $9.62 and a 200 day simple moving average of $10.76. The stock has a market capitalization of $17.57 billion, a PE ratio of -44.13 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, research analysts expect that Astellas Pharma will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.